1
|
Dunham SJB, Avelar-Barragan J, Rothman JA, Adams ED, Faraci G, Forner S, Kawauchi S, Tenner AJ, Green KN, LaFerla FM, MacGregor GR, Mapstone M, Whiteson KL. Sex-specific associations between AD genotype and the microbiome of human amyloid beta knock-in (hAβ-KI) mice. Alzheimers Dement 2024. [PMID: 38572865 DOI: 10.1002/alz.13794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 02/20/2024] [Accepted: 02/23/2024] [Indexed: 04/05/2024]
Abstract
INTRODUCTION Emerging evidence links changes in the gut microbiome to late-onset Alzheimer's disease (LOAD), necessitating examination of AD mouse models with consideration of the microbiome. METHODS We used shotgun metagenomics and untargeted metabolomics to study the human amyloid beta knock-in (hAβ-KI) murine model for LOAD compared to both wild-type (WT) mice and a model for early-onset AD (3xTg-AD). RESULTS Eighteen-month female (but not male) hAβ-KI microbiomes were distinct from WT microbiomes, with AD genotype accounting for 18% of the variance by permutational multivariate analysis of variance (PERMANOVA). Metabolomic diversity differences were observed in females, however no individual metabolites were differentially abundant. hAβ-KI mice microbiomes were distinguishable from 3xTg-AD animals (81% accuracy by random forest modeling), with separation primarily driven by Romboutsia ilealis and Turicibacter species. Microbiomes were highly cage specific, with cage assignment accounting for more than 40% of the PERMANOVA variance between the groups. DISCUSSION These findings highlight a sex-dependent variation in the microbiomes of hAβ-KI mice and underscore the importance of considering the microbiome when designing studies that use murine models for AD. HIGHLIGHTS Microbial diversity and the abundance of several species differed in human amyloid beta knock-in (hAβ-KI) females but not males. Correlations to Alzheimer's disease (AD) genotype were stronger for the microbiome than the metabolome. Microbiomes from hAβ-KI mice were distinct from 3xTg-AD mice. Cage effects accounted for most of the variance in the microbiome and metabolome.
Collapse
Affiliation(s)
- Sage J B Dunham
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| | - Julio Avelar-Barragan
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| | - Jason A Rothman
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| | - Eric D Adams
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| | - Gina Faraci
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| | - Stefania Forner
- Institute for Memory Impairments and Neurological Disorders (UCI MIND), University of California Irvine, Irvine, California, USA
| | - Shimako Kawauchi
- Department of Anatomy and Neurobiology, Developmental Biology Center, University of California Irvine, College of Medicine, Irvine, California, USA
| | - Andrea J Tenner
- Department of Molecular Biology & Biochemistry, Department of Neurobiology and Behavior, Department of Pathology and Laboratory Medicine, School of Medicine, Institute for Memory Impairments and Neurological Disorders (UCI MIND), University of California Irvine, Irvine, California, USA
| | - Kim N Green
- Institute for Memory Impairments and Neurological Disorders (UCI MIND), Department of Neurobiology and Behavior, School of Biological Sciences, Center for Neural Circuit Mapping, University of California Irvine, Irvine, California, USA
| | - Frank M LaFerla
- Institute for Memory Impairments and Neurological Disorders (UCI MIND), Department of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA
| | - Grant R MacGregor
- Department of Developmental and Cell Biology, University of California Irvine, Irvine, California, USA
| | - Mark Mapstone
- Department of Neurology, University of California Irvine, Irvine, California, USA
| | - Katrine L Whiteson
- Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA
| |
Collapse
|
2
|
Mendez Luque LF, Avelar-Barragan J, Nguyen H, Nguyen J, Soyfer EM, Liu J, Chen JH, Mehrotra N, Huang X, Kosiorek HE, Dueck A, Himstead A, Heide E, Lem M, El Alaoui K, Mas E, Scherber RM, Mesa RA, Whiteson KL, Odegaard A, Fleischman AG. The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. Cancer Res Commun 2024; 4:660-670. [PMID: 38391189 PMCID: PMC10913729 DOI: 10.1158/2767-9764.crc-23-0380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 10/12/2023] [Accepted: 02/14/2024] [Indexed: 02/24/2024]
Abstract
PURPOSE Chronic inflammation is integral to myeloproliferative neoplasm (MPN) pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects. Nutrition is a low-risk approach to reduce inflammation and ameliorate symptoms in MPN. We performed a randomized, parallel-arm study to determine the feasibility of an education-focused Mediterranean diet intervention among patients with MPN. EXPERIMENTAL DESIGN We randomly assigned patients with MPN to either a Mediterranean diet or standard U.S. Dietary Guidelines for Americans (USDA). Groups received equal but separate education with registered dietician counseling and written dietary resources. Patients were prospectively followed for feasibility, adherence, and symptom burden assessments. Biological samples were collected at four timepoints during the 15-week study to explore changes in inflammatory biomarkers and gut microbiome. RESULTS The Mediterranean diet was as easy to follow for patients with MPN as the standard USDA diet. Approximately 80% of the patients in the Mediterranean diet group achieved a Mediterranean Diet Adherence Score of ≥8 throughout the entire active intervention period, whereas less than 50% of the USDA group achieved a score of ≥8 at any timepoint. Improvement in symptom burden was observed in both diet groups. No significant changes were observed in inflammatory cytokines. The diversity and composition of the gut microbiome remained stable throughout the duration of the intervention. CONCLUSIONS With dietician counseling and written education, patients with MPN can adhere to a Mediterranean eating pattern. Diet interventions may be further developed as a component of MPN care, and potentially incorporated into the management of other hematologic conditions. SIGNIFICANCE Diet is a central tenant of management of chronic conditions characterized by subclinical inflammation, such as cardiovascular disease, but has not entered the treatment algorithm for clonal hematologic disorders. Here, we establish that a Mediterranean diet intervention is feasible in the MPN patient population and can improve symptom burden. These findings warrant large dietary interventions in patients with hematologic disorders to test the impact of diet on clinical outcomes.
Collapse
Affiliation(s)
- Laura F. Mendez Luque
- University of California, Irvine School of Medicine, Irvine, California
- Teaching and Research Department, Institute of Public Health Services of the State of Baja California, Baja California, Mexico
| | - Julio Avelar-Barragan
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California
| | - Hellen Nguyen
- University of California, Irvine School of Medicine, Irvine, California
| | - Jenny Nguyen
- University of California, Irvine School of Medicine, Irvine, California
| | - Eli M. Soyfer
- University of California, Irvine School of Medicine, Irvine, California
| | - Jiarui Liu
- University of California, Irvine School of Medicine, Irvine, California
| | - Jane H. Chen
- University of California, Irvine School of Medicine, Irvine, California
| | - Nitya Mehrotra
- University of California, Irvine School of Medicine, Irvine, California
| | - Xin Huang
- University of California, Irvine School of Medicine, Irvine, California
| | - Heidi E. Kosiorek
- Department of Quantitative Health Sciences, Mayo Clinic Arizona, Scottsdale, Arizona
| | - Amylou Dueck
- Department of Quantitative Health Sciences, Mayo Clinic Arizona, Scottsdale, Arizona
| | | | - Elena Heide
- University of California, Irvine School of Medicine, Irvine, California
| | - Melinda Lem
- University of California, Irvine School of Medicine, Irvine, California
| | - Kenza El Alaoui
- University of California, Irvine School of Medicine, Irvine, California
| | - Eduard Mas
- University of California, Irvine School of Medicine, Irvine, California
| | | | - Ruben A. Mesa
- Atrium Health, Levine Cancer Institute, Charlotte, North Carolina
| | - Katrine L. Whiteson
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California
| | - Andrew Odegaard
- University of California, Irvine School of Medicine, Irvine, California
| | | |
Collapse
|
3
|
Avelar-Barragan J, Mendez Luque LF, Nguyen J, Nguyen H, Odegaard AO, Fleischman AG, Whiteson KL. Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention. mBio 2023; 14:e0230823. [PMID: 37877698 PMCID: PMC10746218 DOI: 10.1128/mbio.02308-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2023] [Accepted: 09/18/2023] [Indexed: 10/26/2023] Open
Abstract
Myeloproliferative neoplasms (MPNs) are a class of rare hematological malignancies that result in the overproduction of myeloid lineage cells. These malignancies result in increased cytokine production and inflammation, which correlate with worsened symptom burden and prognosis. Other than bone marrow transplantation, there is no cure for myeloproliferative neoplasms. As such, treatments focus on reducing thrombotic risk, inflammation, and symptom burden. Because current pharmacological treatments carry significant side effects, there is a need to explore low-risk therapies that may modulate inflammation and alleviate symptom burden. One potential way to achieve this is adherence to a Mediterranean (MED) diet, which is rich in anti-inflammatory foods, reduces inflammatory biomarkers, and beneficially alters the gut microbiome. We performed a 15-week clinical trial of 28 individuals with MPN who were randomized to dietary counseling based on either a Mediterranean diet or standard U.S. Guidelines for Americans. Our primary objective was to determine whether MPN patients could adopt a Mediterranean eating pattern when supported with dietician counseling. As exploratory endpoints, we investigated the impact of diet and inflammation on the gut microbiome. Using shotgun metagenomic sequencing, we found that microbiome diversity and composition were stable throughout the study duration in both cohorts. Furthermore, we discovered significant differences in the microbiomes between MPN subtypes, such as increased beta-dispersion in subjects with myelofibrosis. Lastly, we found several significant correlations between the abundance of multiple bacterial taxa and cytokine levels. Together, this study provides insight into the interaction between diet, inflammation, and the gut microbiome. IMPORTANCE The gut microbiome serves as an interface between the host and the diet. Diet and the gut microbiome both play important roles in managing inflammation, which is a key aspect of myeloproliferative neoplasm (MPN). Studies have shown that a Mediterranean (MED) diet can reduce inflammation. Therefore, we longitudinally characterized the gut microbiomes of MPN patients in response to Mediterranean or standard 2020 US Guidelines for Americans dietary counseling to determine whether there were microbiome-associated changes in inflammation. We did not find significant changes in the gut microbiome associated with diet, but we did find several associations with inflammation. This research paves the way for future studies by identifying potential mechanistic targets implicated in inflammation within the MPN gut microbiome.
Collapse
Affiliation(s)
- Julio Avelar-Barragan
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, USA
| | - Laura F. Mendez Luque
- Department of Biological Chemistry, University of California Irvine, Irvine, California, USA
| | - Jenny Nguyen
- Division of Hematology/Oncology, University of California Irvine, Irvine, California, USA
| | - Hellen Nguyen
- Division of Hematology/Oncology, University of California Irvine, Irvine, California, USA
| | - Andrew O. Odegaard
- Department of Epidemiology and Biostatistics, University of California Irvine, Irvine, California, USA
| | - Angela G. Fleischman
- Department of Biological Chemistry, University of California Irvine, Irvine, California, USA
- Division of Hematology/Oncology, University of California Irvine, Irvine, California, USA
| | - Katrine L. Whiteson
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, USA
| |
Collapse
|
4
|
Mendez Luque LF, Avelar-Barragan J, Nguyen H, Nguyen J, Soyfer EM, Liu J, Chen JH, Mehrotra N, Kosiorek HE, Dueck A, Himstead A, Heide E, Lem M, Alaoui KE, Marin EM, Scherber RM, Mesa RA, Whiteson KL, Odegaard A, Fleischman AG. The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase. medRxiv 2023:2023.05.09.23289740. [PMID: 37214789 PMCID: PMC10197802 DOI: 10.1101/2023.05.09.23289740] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Purpose Chronic inflammation is integral to Myeloproliferative Neoplasm (MPN) pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects. Nutrition is a low-risk approach to reduce inflammation and ameliorate symptoms in MPN. We performed a randomized, parallel-arm study to determine the feasibility of an education-focused Mediterranean diet intervention among MPN patients. Experimental Design We randomly assigned participants to either a Mediterranean diet or standard US Dietary Guidelines for Americans (USDA). Groups received equal but separate education with registered dietician counseling and written dietary resources. Patients were prospectively followed for feasibility, adherence, and symptom burden assessments. Biological samples were collected at four time points during the 15-week study to explore changes in inflammatory biomarkers and gut microbiome. Results The Mediterranean diet was as easy to follow for MPN patients as the standard USDA diet. Over 80% of the patients in the Mediterranean diet group achieved a Mediterranean Diet Adherence Score of ≥8 throughout the entire active intervention period, whereas less than 50% of the USDA group achieved a score of ≥8 at any time point. Improvement in symptom burden was observed in both diet groups. No significant changes were observed in inflammatory cytokines. The diversity and composition of the gut microbiome remained stable throughout the duration of the intervention. Conclusions With dietician counseling and written education MPN patients can adhere to a Mediterranean eating pattern. Diet interventions may be further developed as a component of MPN care, and potentially even be incorporated into the management of other chronic clonal hematologic conditions.
Collapse
Affiliation(s)
- Laura F. Mendez Luque
- University of California, Irvine School of Medicine
- Teaching and Research Department, Institute of Public Health Services of the State of Baja California
| | | | | | - Jenny Nguyen
- University of California, Irvine School of Medicine
| | | | - Jiarui Liu
- University of California, Irvine School of Medicine
| | - Jane H. Chen
- University of California, Irvine School of Medicine
| | | | - Heidi E. Kosiorek
- Department of Quantitative Health Sciences, Mayo Clinic Arizona, Scottsdale, AZ
| | - Amylou Dueck
- Department of Quantitative Health Sciences, Mayo Clinic Arizona, Scottsdale, AZ
| | | | - Elena Heide
- University of California, Irvine School of Medicine
| | - Melinda Lem
- University of California, Irvine School of Medicine
| | | | | | | | - Ruben A. Mesa
- Atrium Health, Levine Cancer Institute, Charlotte, NC
| | - Katrine L. Whiteson
- Department of Molecular Biology and Biochemistry, University of California Irvine
| | | | | |
Collapse
|
5
|
Mittal E, Oliver A, Alaoui KE, Haunschild C, Avelar-Barragan J, Luque LFM, Whiteson K, Fleischman AG. Abstract 5908: Specific gut microbial community is associated with specific cancer types: A strategy for cancer detection and prevention. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Cancer is the second leading cause of death in the world. Unfortunately, survival rates for cancer patients have stayed poor for many decades. Thus, there is an unmet need to identify novel strategies for early cancer detection and prevention. Recent studies suggest that the gut microbiome including bacteria may have a role in cancer initiation and progression. These bacteria play a vital role in maintaining homeostasis in the body. An imbalance in the bacterial composition may cause diseases including cancer. This evidence led us to hypothesize that the changes in the composition of the gut microbiome can be used as a biomarker for early cancer detection. To test this hypothesis, we focused on analyzing the microbial community of colorectal and blood cancers, which have poor survival rates.
Methods and Results: To analyze the association of cancer with the microbiome, we used a published microbiome dataset of leukemic and healthy individuals that were collected by sequencing stool samples (Oliver et al., 2022). We identified that specific bacteria are either abundant, such as Faecalibacterium (1.17 fold), or reduced, such as Clostridium (0.32 fold, p value=0.0029), in leukemia patients compared to healthy controls. We observed similar correlations by analyzing the published colorectal cancer data (Flemer et al., 2017) in which Prevotella increased by 3.75 fold and Escherichia/Shigella increased by 4.0 fold in colorectal cancer while Blautia is reduced compared to healthy controls. Faecalibacterium, which is abundant in leukemia, is reduced in colorectal cancer. Further, we found that treatment of leukemia patients normalized the abundance of these bacteria to the level of healthy patients. To improve analysis efficiency, we applied machine learning algorithms to predict the presence of cancer in patients based on the composition of bacteria, age, gender, and symptoms. Among the tested algorithms, the decision tree and Random Forest both had very high false-negative rates, with 45.5% and 40% respectively, as well as having low sensitivities, with 50% and 60% respectively. The support Vector Machine had a suboptimal false-negative rate of 28.6% and good sensitivity of 80%. Finally, the Neural network had a good false-negative rate of 16.7% and great sensitivity of 90%. Overall, our results suggest that different cancers have an abundance of specific bacteria that can be used as biomarkers for cancer detection.
Conclusion: We demonstrate that the increased abundance of certain bacteria in the microbiome can be used as a biomarker for cancer detection. Our data set was small for this project, but the machine learning approaches can be used to further predict cancer These are clinically relevant findings as a microbiome test would be non-invasive and easily accessible that can be performed at a routine checkup.
Citation Format: Ekansh Mittal, Andrew Oliver, Kenza El Alaoui, Carolyn Haunschild, Julio Avelar-Barragan, Laura F. Mendez Luque, Katrine Whiteson, Angela G. Fleischman. Specific gut microbial community is associated with specific cancer types: A strategy for cancer detection and prevention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5908.
Collapse
|
6
|
Oliver A, El Alaoui K, Haunschild C, Avelar-Barragan J, Mendez Luque LF, Whiteson K, Fleischman AG. Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State. Microbiol Spectr 2022; 10:e0003222. [PMID: 35475626 PMCID: PMC9241690 DOI: 10.1128/spectrum.00032-22] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Accepted: 04/11/2022] [Indexed: 11/26/2022] Open
Abstract
The capacity of the human microbiome to modulate inflammation in the context of cancer is becoming increasingly clear. Myeloproliferative neoplasms (MPNs) are chronic hematologic malignancies in which inflammation plays a key role in disease initiation, progression, and symptomatology. To better understand the composition of the gut microbiome in patients with MPN, triplicate fecal samples were collected from 25 MPN patients and 25 non-MPN controls. Although most of the variance between the microbial community compositions could be attributed to the individual (permutational analysis of variance [PERMANOVA], R2 = 0.92, P = 0.001), 1.7% of the variance could be attributed to disease status (MPN versus non-MPN). When a more detailed analysis was performed, significantly fewer reads mapping to a species of Phascolarctobacterium, a microbe previously associated with reduced inflammation, were found in MPNs. Further, our data revealed an association between Parabacteroides and tumor necrosis factor alpha (TNF-α), an inflammatory cytokine elevated in MPNs. Taken together, our results indicate a significant difference in the microbiome of MPN patients compared to non-MPN controls, and we identify specific species which may have a role in the chronic inflammation central to this disease. IMPORTANCE MPNs are chronic blood cancers in which inflammation plays a key role in disease initiation, progression, and symptomatology. The gut microbiome modulates normal blood development and inflammation and may also impact the development and manifestation of blood cancers. Therefore, the microbiome may be an important modulator of inflammation in MPN and could potentially be leveraged therapeutically in this disease. However, the relationship between the gut microbiome and MPNs has not been defined. Therefore, we performed an evaluation of the MPN microbiome, comparing the microbiomes of MPN patients with healthy donors and between MPN patients with various states of disease.
Collapse
Affiliation(s)
- Andrew Oliver
- Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, California, USA
| | - Kenza El Alaoui
- Division of Hematology/Oncology, School of Medicine, University of California Irvine, Irvine, California, USA
- Department of Internal Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Carolyn Haunschild
- Division of Gynecologic Oncology, School of Medicine, University of California Irvine, Irvine, California, USA
| | - Julio Avelar-Barragan
- Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, California, USA
| | - Laura F. Mendez Luque
- Biological Chemistry, School of Medicine, University of California Irvine, Irvine, California, USA
| | - Katrine Whiteson
- Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, California, USA
| | - Angela G. Fleischman
- Division of Hematology/Oncology, School of Medicine, University of California Irvine, Irvine, California, USA
- Biological Chemistry, School of Medicine, University of California Irvine, Irvine, California, USA
- Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
| |
Collapse
|
7
|
DeDecker L, Coppedge B, Avelar-Barragan J, Karnes W, Whiteson K. Microbiome distinctions between the CRC carcinogenic pathways. Gut Microbes 2021; 13:1854641. [PMID: 33446008 PMCID: PMC8288036 DOI: 10.1080/19490976.2020.1854641] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2020] [Revised: 10/01/2020] [Accepted: 11/10/2020] [Indexed: 02/06/2023] Open
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer, the third leading cause of cancer-related deaths, and has been on the rise among young adults in the United States. Research has established that the colonic microbiome is different in patients with CRC compared to healthy controls, but few studies have investigated if and how the microbiome may relate to CRC progression through the serrated pathway versus the adenoma-carcinoma sequence.Our view is that progress in CRC microbiome research requires consideration of how the microbiome may contribute to CRC carcinogenesis through the distinct pathways that lead to CRC, which could enable the creation of novel and tailored prevention, screening, and therapeutic interventions. We first highlight the limitations in existing CRC microbiome research and offer corresponding solutions for investigating the microbiome's role in the adenoma-carcinoma sequence and serrated pathway. We then summarize the findings in the select human studies that included data points related to the two major carcinogenic pathways. These studies investigate the microbiome in CRC carcinogenesis and 1) utilize mucosal samples and 2) compare polyps or tumors by histopathologic type, molecular/genetic type, or location in the colon.Key findings from these studies include: 1) Fusobacterium is associated with right-sided, more advanced, and serrated lesions; 2) the colons of people with CRC have bacteria typically associated with normal oral flora; and 3) colons from people with CRC have more biofilms, and these biofilms are predominantly located in the proximal colon (single study).
Collapse
Affiliation(s)
- Lauren DeDecker
- School of Medicine, University of California, Irvine, California, USA
| | - Bretton Coppedge
- School of Biological Sciences, University of California, Irvine, California, USA
| | | | - William Karnes
- School of Medicine, University of California, Irvine, California, USA
| | - Katrine Whiteson
- School of Biological Sciences, University of California, Irvine, California, USA
| |
Collapse
|